v3.26.1
Shareholders' Equity
 12 Months Ended
Jun. 30, 2026
Equity [Abstract]  
Shareholders' Equity
11. Shareholders' Deficit
At June 30, 2026 and 2025, authorized capital shares consisted of the following: 750 million Class A common shares, without par value; 5 million Class B common shares, without par value; and 500 thousand non-voting preferred shares, without par value. The
Class A common shares and Class B common shares are collectively referred to below as “common shares.” Holders of common shares are entitled to share equally in any dividends declared by the Board of Directors and to participate equally in all distributions of assets upon liquidation. Generally, the holders of Class A common shares are entitled to one vote per share, and the holders of Class B common shares are entitled to one-fifth of one vote per share on proposals presented to shareholders for vote. Under certain circumstances, the holders of Class B common shares are entitled to vote as a separate class. Only Class A common shares were outstanding at June 30, 2026 and 2025.
We repurchased $2.9 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2026, 2025, and 2024, as described below. We funded the repurchases with available cash. The common shares repurchased are held in treasury to be used for general corporate purposes.
The following table presents the share repurchase programs executed during fiscal 2026, 2025, and 2024:
Quarter EnteredDate ConcludedAggregate Purchase Price
(in millions)		Initial Shares
(in millions)		Reference PriceFinal Shares
(in millions)		Weighted Average Price per Common Share
Q4 FY266/26/2026$3501.5$182.500.2$206.37
Q3 FY264/20/2026$2500.9$215.420.3$209.55
Q2 FY26
12/15/2025$3751.6$190.220.3$200.00
Q1 FY26
10/31/2025$3752.0$148.120.4$151.88
Q3 FY25
3/11/2025$3752.4$125.330.6$125.87
Q1 FY25
10/30/2024$3752.7$109.650.7$110.10
Q2 FY2412/13/2023$2502.0$101.660.4$103.67
Q1 FY2410/31/2023$5004.4$90.571.3$88.22
During fiscal 2026 and 2025, we paid $8 million and $15 million for excise taxes, respectively, related to the completion of prior ASR programs.
During fiscal 2025, we retired 56 million of common stock shares without par value.
Accumulated Other Comprehensive Loss
The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:
(in millions)Foreign
Currency
Translation
Adjustments and Other		Unrealized
Gain/(Loss) on
Derivatives,
net of tax		Accumulated Other
Comprehensive
Loss
Balance at June 30, 2024$(138)$(29)$(167)
Other comprehensive income/(loss), before reclassifications(3)13 10 
Amounts reclassified to earnings— 2 2 
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax benefit of $6 million
(3)15 12 
Balance at June 30, 2025(141)(14)(155)
Other comprehensive income, before reclassifications1 5 6 
Amounts reclassified to earnings— (16)(16)
Total other comprehensive income/(loss) attributable to Cardinal Health, Inc., net of tax expense of $9 million
1 (11)(10)
Balance at June 30, 2026$(140)$(25)$(165)